glp 1 medication list The Boom in New Weight Loss Drugs: What Prehospital Caregivers Need to Know You've reached your weight loss

Studies using GIP-Cre mice have demonstrated that GIP receptors are expressed in key brain regions involved in feeding regulation, including the ARC, paraventricular nucleus (PVN), and DMH of the hypothalamus, as well as the area postrema (AP) of the medulla [31]

Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation

Certain GLP-1 formulations have demonstrated cardiovascular benefits in clinical trials, leading to specific FDA approvals: Victoza, Ozempic, and Trulicity are approved for reducing major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, while Wegovy is approved for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight

This Review profiles established and emerging GLP-1-based medicines, discussing optimization of pharmacokinetics and tolerability, engagement of new therapeutically useful pathways and safety aspects

Triple agonists with GLP1, GIP and glucagon Given the efficacy and benefits of the dual GLP-1/GIP RA tirzepatide and the dual GLP-1/glucagon RA, a triple agonist targeting all three receptors (GLP-1/GIP/glucagon) may result in superior WL and glycaemic control than dual agonists